May Shawi

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 32

Top Topics

Endoplasmic Reticulum

Editorial Comment

Juvenile Idiopathic Arthritis

Top Venues

Clinical rheumatology

Rheumatology and therapy

Arthritis & rheumatology (Hoboken, N.J.)

This page only lists publications with an associated author ORCID identifier.

Publications

Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 76 (6) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Xenofon Baraliakos, Dafna D Gladman, Soumya D Chakravarty, Cinty Gong, May Shawi, Emmanouil Rampakakis, Kishimoto Mitsumasa, Enrique Roberto Soriano, Phillip J Mease
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies. Rheumatology advances in practice 8 (2) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of IL-23 Signaling With Guselkumab in Biologic-Naïve Patients Versus TNF Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 76 (6) (2024)
Xenofon Baraliakos, Dafna D Gladman, Soumya D Chakravarty, Cinty Gong, May Shawi, Emmanouil Rampakakis, Kishimoto Mitsumasa, Enrique Roberto Soriano, Phillip J Mease
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies. Rheumatology advances in practice 8 (2) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Bruce E Strober, Laura C Coates, Mark G Lebwohl, Atul Deodhar, Evan Leibowitz, Katelyn Rowland, Alexa P Kollmeier, Megan Miller, Yanli Wang, Shu Li, Soumya D Chakravarty, Daphne Chan, May Shawi, Ya-Wen Yang, Diamant Thaҫi, Proton Rahman
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Drug safety (2023)
Alice B Gottlieb, Iain B McInnes, Proton Rahman, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Frederic Lavie, Phillip J Mease
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD open 9 (1) (2023)
Alice B Gottlieb, Iain B McInnes, Proton Rahman, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Frederic Lavie, Phillip J Mease
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD open 9 (1) (2023)
Phillip J Mease, Alice B Gottlieb, Philip S Helliwell, Iain B McInnes, Soumya D Chakravarty, Emmanouil Rampakakis, Alexa P Kollmeier, Xie L Xu, May Shawi, Frederic Lavie, Kishimoto Mitsumasa, Proton Rahman
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. Clinical rheumatology (2023)
Proton Rahman, Wolf-Henning Boehncke, Phillip J Mease, Alice B Gottlieb, Iain B McInnes, May Shawi, Yanli Wang, Shihong Sheng, Alexa P Kollmeier, Elke Theander, Jenny Yu, Evan Leibowitz, A Marilise Marrache, Laura C Coates
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis. The Journal of rheumatology (2023)
Phillip J Mease, Dafna D Gladman, Denis Poddubnyy, Soumya D Chakravarty, May Shawi, Alexa P Kollmeier, Xie L Xu, Stephen Xu, Atul Deodhar, Xenofon Baraliakos
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study. Rheumatology and therapy (2023)
Arthur Kavanaugh, Xenofon Baraliakos, Sheng Gao, Warner Chen, Kristen M Sweet, Soumya D Chakravarty, Qingxuan Song, May Shawi, Proton Rahman
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials. Advances in therapy (2023)
Ana Maria Orbai, Soumya D Chakravarty, Yin You, May Shawi, Ya-Wen Yang, Joseph Frank Merola
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis. Dermatology and therapy (2023)
Dafna D Gladman, Phillip J Mease, Paul Bird, Enrique Roberto Soriano, Soumya D Chakravarty, May Shawi, Frederic Lavie, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul A Deodhar, Mikkel Østergaard, Xenofon Baraliakos
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé. Annals of the rheumatic diseases (2022)